BACKGROUND: Patient reporting of the severity and impact of symptoms is an essential component of cancer symptom management and cancer treatment clinical trials. In multinational clinical trials, cultural and linguistic variations in patient-reported outcomes instruments could confound the interpretation of study results. METHODS: The severity and interference of multiple symptoms in 1433 cancer patients with mixed diagnoses and treatment status from the United States, China, Japan, Russia, and Korea were measured with psychometrically validated language versions of the M. D. Anderson Symptom Inventory (MDASI). Mixed-effect ordinal probit regression models were fitted to the pooled data to compare the magnitude of the effect of "country" (nation and linguistic factors) with between-subjects effects on symptom reporting, adjusted for patient and clinical factors (age, sex, performance status, and chemotherapy status). RESULTS: For the pooled sample, fatigue, disturbed sleep, distress, pain, and lack of appetite were the most severe patient-reported MDASI symptoms. The magnitude of the variance of the country random effects was only one-fourth to one-half of the interpatient variation (sigma(2) = 0.23-0.46) for all symptoms, except nausea and vomiting. CONCLUSIONS: Cultural and linguistic variations in symptom reporting among the five language versions of the validated MDASI were limited. Ordinal probit modeling provided a simple mechanism for accounting for cultural and linguistic differences in patient populations. The equivalence among MDASI translations in this study suggests that symptom ratings collected from various cultural and language groups using the MDASI can be interpreted in a similar way in oncology practice, clinical trials, and clinical research.
BACKGROUND:Patient reporting of the severity and impact of symptoms is an essential component of cancer symptom management and cancer treatment clinical trials. In multinational clinical trials, cultural and linguistic variations in patient-reported outcomes instruments could confound the interpretation of study results. METHODS: The severity and interference of multiple symptoms in 1433 cancerpatients with mixed diagnoses and treatment status from the United States, China, Japan, Russia, and Korea were measured with psychometrically validated language versions of the M. D. Anderson Symptom Inventory (MDASI). Mixed-effect ordinal probit regression models were fitted to the pooled data to compare the magnitude of the effect of "country" (nation and linguistic factors) with between-subjects effects on symptom reporting, adjusted for patient and clinical factors (age, sex, performance status, and chemotherapy status). RESULTS: For the pooled sample, fatigue, disturbed sleep, distress, pain, and lack of appetite were the most severe patient-reported MDASI symptoms. The magnitude of the variance of the country random effects was only one-fourth to one-half of the interpatient variation (sigma(2) = 0.23-0.46) for all symptoms, except nausea and vomiting. CONCLUSIONS: Cultural and linguistic variations in symptom reporting among the five language versions of the validated MDASI were limited. Ordinal probit modeling provided a simple mechanism for accounting for cultural and linguistic differences in patient populations. The equivalence among MDASI translations in this study suggests that symptom ratings collected from various cultural and language groups using the MDASI can be interpreted in a similar way in oncology practice, clinical trials, and clinical research.
Authors: Robert Swarm; Doralina L Anghelescu; Costantino Benedetti; Barry Boston; Charles Cleeland; Nessa Coyle; Oscar A Deleon-Casasola; Anthony Eidelman; June G Eilers; Betty Ferrell; Stuart A Grossman; Nora A Janjan; Michael H Levy; Maureen Lynch; Gustavo S Montana; Suzanne Nesbit; Linda Oakes; Eugenie A Obbens; Judy Paice; Karen L Syrjala; Susan Urba; Sharon M Weinstein Journal: J Natl Compr Canc Netw Date: 2007-09 Impact factor: 11.908
Authors: C Benedetti; C Brock; C Cleeland; N Coyle; J E Dubé; B Ferrell; S Hassenbusch; N A Janjan; M J Lema; M H Levy; M J Loscalzo; M Lynch; C Muir; L Oakes; A O'Neill; R Payne; K L Syrjala; S Urba; S M Weinstein Journal: Oncology (Williston Park) Date: 2000-11 Impact factor: 2.990
Authors: Tito R Mendoza; Xin Shelley Wang; Charles Lu; Guadalupe R Palos; Zhongxing Liao; Gary M Mobley; Shitij Kapoor; Charles S Cleeland Journal: Oncologist Date: 2011-02-01
Authors: Zarnie Lwin; Alexander Broom; Rasha Cosman; Ann Livingstone; Kate Sawkins; Phillip Good; Emma Kirby; Eng-Siew Koh; Elizabeth Hovey Journal: Neurooncol Pract Date: 2014-06-25
Authors: Carolyn Miller Reilly; Deborah Watkins Bruner; Sandra A Mitchell; Lori M Minasian; Ethan Basch; Amylou C Dueck; David Cella; Bryce B Reeve Journal: Support Care Cancer Date: 2013-01-12 Impact factor: 3.603
Authors: Charles S Cleeland; Tito R Mendoza; Xin Shelley Wang; Jeanie F Woodruff; Guadalupe R Palos; Stephen P Richman; Arlene Nazario; Garrett R Lynch; Kai-Ping Liao; Gary M Mobley; Charles Lu Journal: J Clin Oncol Date: 2011-06-20 Impact factor: 44.544
Authors: Desiree Jones; Elisabeth G Vichaya; Charles S Cleeland; Lorenzo Cohen; Seema M Thekdi; Xin Shelley Wang; Michael J Fisch Journal: J Oncol Pract Date: 2013-11-26 Impact factor: 3.840
Authors: Xin Shelley Wang; Fengmin Zhao; Michael J Fisch; Ann M O'Mara; David Cella; Tito R Mendoza; Charles S Cleeland Journal: Cancer Date: 2014-02-01 Impact factor: 6.860
Authors: Mary H Sailors; Diane C Bodurka; Ibrahima Gning; Lois M Ramondetta; Loretta A Williams; Tito R Mendoza; Sonika Agarwal; Charlotte C Sun; Charles S Cleeland Journal: Gynecol Oncol Date: 2013-05-15 Impact factor: 5.482
Authors: Tito R Mendoza; Fengmin Zhao; Charles S Cleeland; Lynne I Wagner; Linda J Patrick-Miller; Michael J Fisch Journal: Clin Breast Cancer Date: 2013-06-28 Impact factor: 3.225